Active specific immunotherapy with the vaccine preparation NGcGM3 / VSSP in patients with small cell lung cancer

Trial Profile

Active specific immunotherapy with the vaccine preparation NGcGM3 / VSSP in patients with small cell lung cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs N-glycolyl GM3 vaccine (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 May 2018 Status changed from not yet recruiting to recruiting.
    • 17 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top